We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that...
Preparing to submit response to the FDA’s CRL for neffy® (epinephrine nasal spray) in Type I allergic reactions in early Q2 2024, following successful completion of neffy repeat dose nasal...
Significant unmet need with 80-90% of patients with current epinephrine Rx not using as directed, and only ~15% of diagnosed severe Type I allergy population with a current epinephrine...
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.06 | -0.713436385256 | 8.41 | 8.83 | 7.66 | 438570 | 8.30454474 | CS |
4 | -1.87 | -18.2974559687 | 10.22 | 10.22 | 7.66 | 535084 | 9.05333467 | CS |
12 | 2.1 | 33.6 | 6.25 | 11.27 | 6.18 | 727781 | 8.77798338 | CS |
26 | 4.9 | 142.028985507 | 3.45 | 11.27 | 3.38 | 594909 | 7.04444614 | CS |
52 | 1.83 | 28.0674846626 | 6.52 | 11.27 | 2.55 | 1036770 | 6.40563773 | CS |
156 | 3.07 | 58.1439393939 | 5.28 | 11.27 | 2.55 | 786396 | 6.49752104 | CS |
260 | 3.07 | 58.1439393939 | 5.28 | 11.27 | 2.55 | 786396 | 6.49752104 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions